1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2023-11-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| _version_ | 1797630767469166592 |
|---|---|
| author | Bom Park Hyojoo Bang So Woon Kim Sunjung Cho Youngsam Kim Suyoon Kim Minwoo Kim Youngjin Park Jun-Eui Park |
| author_facet | Bom Park Hyojoo Bang So Woon Kim Sunjung Cho Youngsam Kim Suyoon Kim Minwoo Kim Youngjin Park Jun-Eui Park |
| author_sort | Bom Park |
| collection | DOAJ |
| first_indexed | 2024-03-11T11:12:48Z |
| format | Article |
| id | doaj.art-c037a609279946c28fd41f7066c78d16 |
| institution | Directory Open Access Journal |
| issn | 2051-1426 |
| language | English |
| last_indexed | 2024-03-11T11:12:48Z |
| publishDate | 2023-11-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj.art-c037a609279946c28fd41f7066c78d162023-11-11T19:35:08ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262023-11-0111Suppl 110.1136/jitc-2023-SITC2023.11791179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerabilityBom Park0Hyojoo Bang1So Woon Kim2Sunjung Cho3Youngsam Kim4Suyoon Kim5Minwoo Kim6Youngjin Park7Jun-Eui Park8Mustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of KoreaMustbio, Suwon-si, Gyeonggi-do, Republic of Korea |
| spellingShingle | Bom Park Hyojoo Bang So Woon Kim Sunjung Cho Youngsam Kim Suyoon Kim Minwoo Kim Youngjin Park Jun-Eui Park 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability Journal for ImmunoTherapy of Cancer |
| title | 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability |
| title_full | 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability |
| title_fullStr | 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability |
| title_full_unstemmed | 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability |
| title_short | 1179 MB501: a novel anti-PD-1 x IL-2 variant enhancing the anti-tumor efficacy by empowering activated T cells with improved drug tolerability |
| title_sort | 1179 mb501 a novel anti pd 1 x il 2 variant enhancing the anti tumor efficacy by empowering activated t cells with improved drug tolerability |
| work_keys_str_mv | AT bompark 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT hyojoobang 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT sowoonkim 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT sunjungcho 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT youngsamkim 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT suyoonkim 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT minwookim 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT youngjinpark 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability AT juneuipark 1179mb501anovelantipd1xil2variantenhancingtheantitumorefficacybyempoweringactivatedtcellswithimproveddrugtolerability |